BiotechTube

Denileukin Diftitox (Ontak)

Phase 1Terminated
1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Myeloma

Conditions

Multiple Myeloma

Trial Timeline

Nov 1, 2010 → May 1, 2013

NCT ID
NCT01251952

About Denileukin Diftitox (Ontak)

Denileukin Diftitox (Ontak) is a phase 1 stage product being developed by Eisai for Multiple Myeloma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01251952. Target conditions include Multiple Myeloma.

What happened to similar drugs?

20 of 20 similar drugs in Multiple Myeloma were approved

Approved (20) Terminated (0) Active (0)
✅Mirabegron + PlaceboAstellas PharmaApproved
✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
✅TeclistamabJohnson & JohnsonApproved
✅BortezomibJohnson & JohnsonApproved
✅DaratumumabJohnson & JohnsonApproved
✅Mavenclad®MerckApproved
✅Mavenclad®MerckApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01432483Pre-clinicalCompleted
NCT01251952Phase 1Terminated

Competing Products

20 competing products in Multiple Myeloma

See all competitors
ProductCompanyStageHype Score
mRNA-1195ModernaPhase 2
0
NEX-20ANanexa ABPhase 1
23
mRNA-2736ModernaPhase 1
0
mRNA-2808ModernaPhase 2
0
Placebo + PirtobrutinibEli LillyPhase 2
27
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
32
agenT-797MiNK TherapeuticsPhase 1
19
Duloxetine Hydrochloride (HCI) + PlaceboEli LillyPhase 3
40
TemferonGenenta SciencePhase 1/2
14
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
47
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
CS-0777 tablets + CS-0777 tablets + CS-0777 tabletsDaiichi SankyoPhase 1
29
ASP7487, Velcade, DexamethasoneAstellas PharmaPhase 1/2
24
PHE885NovartisPhase 2
27
Mirabegron + PlaceboAstellas PharmaApproved
43
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
43
PalonosetronEisaiPhase 2
35
BIW-8962Kyowa KirinPhase 1
21
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)Kyowa KirinPhase 2
35
KW-2478 + BortezomibKyowa KirinPhase 1/2
32